Side-by-side · Research reference

CartalaxvsLiraglutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BFDA-ApprovedFlagship14/45 cited

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

Liraglutide

Daily GLP-1 RA · FDA-Approved

0.6–3.0 mgDaily doseSAXENDA (liraglutide) injectio 2014

5–10%Body-weight ↓SAXENDA (liraglutide) injectio 2014

~13 hrHalf-lifeSAXENDA (liraglutide) injectio 2014

SQ · Abdomen / thigh / arm · Once daily

01Mechanism of Action

Parameter

Cartalax

Liraglutide

Primary target

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014

Pathway

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014 Marso 2016

Downstream effect

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016

Feedback intact?

—

Glucose-dependent insulin release preserves physiological feedback

Origin

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014

Antibody development

—

02Dosage Protocols

Parameter

Cartalax

Liraglutide

Animal model dose

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

—

Human dosing

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

—

Evidence basis

Animal mechanistic studies only

FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016 SAXENDA (liraglutide) injectio 2014

Standard dose (T2D, Victoza)

—

1.2–1.8 mg / daySAXENDA (liraglutide) injectio 2014

Standard dose (weight, Saxenda)

—

3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014

Frequency

—

Once daily, same time each day

Titration schedule

—

0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks

Mitigates GI side effects.

Duration

—

Indefinite for chronic indication

Reconstitution

—

Pre-filled commercial pen (no reconstitution)

Timing

—

Any time of day; consistent

Half-life

—

~13 hrSAXENDA (liraglutide) injectio 2014

03Metabolic / Fat Loss Evidence

Parameter

Cartalax

Liraglutide

Fat loss evidence

None — primary target is cartilage and bone tissue, not adipose

—

04Side Effects & Safety

Parameter

Cartalax

Liraglutide

Documented adverse effects

None reported in indexed animal studies

—

Human safety data

Not available in PubMed-indexed literature

—

GI symptoms

—

Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014

Pancreatitis risk

—

Rare; discontinue if suspected

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014

Hypoglycemia

—

Low risk as monotherapy; elevated with sulfonylureas / insulin

Heart rate

—

Modest ↑ resting HR (~2-3 bpm)

Cardiovascular benefit

—

↓ MACE in high-risk T2D (LEADER trial)Marso 2016

Pregnancy / OB

—

Contraindicated

Absolute Contraindications

Cartalax

·Unknown due to lack of human clinical trial data

Liraglutide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to liraglutide

Relative Contraindications

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

Liraglutide

·Severe gastroparesis
·History of pancreatitis
·Severe gastrointestinal disease

05Administration Protocol

Parameter

Cartalax

Liraglutide

1. Route

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

Commercial pre-filled pen, no reconstitution required.

2. Frequency

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Storage

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

Once daily, same time each day. Take with or without food.

4. Storage

—

Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.

5. Needle

—

Pen-supplied 32G needle.